Cardiovascular Risks and Management of Diabetes

Introduction to Cardiovascular Risks

• The American Heart Association and the American College of Cardiology note that certain medications, such as sulfonylureas, increase the risk of hypoglycemia, which can be particularly dangerous in patients who have already experienced a stroke or have established coronary artery disease 1, 2

Medication Management and Cardiovascular Risks

• Major randomized clinical trials (UKPDS, ADVANCE, BARI-2D) have not shown an increase in heart failure or cardiovascular events with sulfonylureas compared to conventional therapies, but sulfonylureas carry a significant risk of hypoglycemia 1
• The CAROLINA study found no significant difference in the risk of cardiovascular death, myocardial infarction, or non-fatal stroke between glimepiride and linagliptine, suggesting that some sulfonylureas may be safer than others in terms of cardiovascular risk 2
• SGLT-2 inhibitors have demonstrated significant cardiovascular benefits, including a reduction in hospitalizations for heart failure, as noted by the American College of Cardiology 1
• GLP-1 receptor agonists have also shown cardiovascular benefits in certain studies, according to the American College of Cardiology 3

Patient Monitoring and Special Considerations

• The American Diabetes Association and the American College of Cardiology recommend close monitoring of blood glucose levels to avoid hypoglycemia, especially when initiating or adjusting medication doses, and being particularly vigilant in elderly patients who are more sensitive to hypoglycemia 2, 4
• Patients with chronic kidney disease require dose adjustments and careful monitoring, as recommended by the American Journal of Kidney Diseases 5

Treatment Guidelines and Recommendations

• The American College of Cardiology and the American Diabetes Association recommend metformin as the first-line treatment for type 2 diabetes, due to its favorable cardiovascular risk profile and low risk of hypoglycemia 1, 4
• If a sulfonylurea must be used, prefer glipizide, gliclazide, or glimepiride over glyburide, and start with low doses and titrate gradually to minimize hypoglycemia risk, as recommended by Diabetes Care and the American Journal of Kidney Diseases 6, 5
• Consider alternatives to sulfonylureas in patients with established cardiovascular disease, as recommended by the American Heart Association and Circulation 2
• The following table summarizes the characteristics of different sulfonylureas:

6, 5, 7